|
|
|
|
|
|
|
|
|
|
Previous: AQUILA BIOPHARMACEUTICALS INC, 3, 1996-10-31 |
Next: FREEDOM GROUP OF TAX EXEMPT FUNDS, DEF 14A, 1996-10-31 |
U.S. SECURITIES AND EXCHANGE COMMISSION
FORM 3 Washington, DC 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
1. Name and Address of Reporting Person* 2. Date of Event
Requiring
Taunton-Rigby Alison Statement
(Month/Day/Year)
(Last) (First) (Middle) 10/21/96
c/o AQUILA BIOPHARMACEUTICALS, INC. 3. IRS or Social
365 PLANTATION STREET Security
(Street) Number of Reporting
Person (Voluntary)
WORCESTER MA 01605
(City) (State) (Zip)
4. Issuer Name and Ticker or Trading Symbol
AQUILA BIOPHARMACEUTICALS, INC. (AQLA)
5. Relationship of Reporting Person 6. If Amendment, Date of
to Issuer (Check all applicable) Original
___Director ___10% Owner (Month/Day/Year)
_X_Officer (give ___Other (specify
title below) below)
_PRESIDENT AND CEO__________ 7. Individual or Joint/Group
Filing
(Check applicable line)
__X__ Form filed by One
Reporting Person
_____ Form filed by More than
One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
I. Title of Security 2. Amount of Securities
(Instr. 4) Beneficially Owned
(Instr. 4)
3. Ownership 4. Nature of Indirect Beneficial Ownership
Form: Direct (Instr. 4)
(D) or Indirect
(I) (Instr. 5)
*If the Form is filed by more than one Reporting Person, see Instruction
5(b)(v). Reminder: Report on a separate line for each class of
securities beneficially owned directly or indirectly.
(Over)
(Print or Type Responses)
FORM 3 (continued) Table II - Derivative Securities Beneficially
Owned
(e.g. puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security 2. Date Exercisa- 3. Title and Amount
(Instr. 4) ble and Expi- of Securities
ration Date Underlying
(Month/Day/ Derivative
Year) Security
(Instr. 4)
Date Expira- Amount
Exercis- tion Title or Num.
able Date of
shares
STOCK OPTION* 12/15/ 12/15/ COMMON
RIGHT TO BUY 1995 2005 STOCK 104,043
4. Conver- 5. Owner- 6. Nature of Indirect
sion or ship Beneficial Ownership
Exercise Form of (Instr. 5)
Price of Deriva-
Deriva- tive
tive Security:
Security: Direct
(D) or
Indirect
(I)
(Instr. 5)
$2.80 D
Explanation of Responses: *OPTION TO PURCHASE CAMBRIDGE BIOTECH
CORPORATION COMMON STOCK, CONVERTED TO AN OPTION TO PURCHASE
AQUILA BIOPHARMACEUTICALS, INC. COMMON STOCK AT AN EXCHANGE RATE
OF 7.569 SHARES OF CAMBRIDGE BIOTECH CORPORATION COMMON STOCK FOR
1 SHARE OF AQUILA BIOPHARMACEUTICALS, INC. COMMON STOCK.
**Intentional misstatements or omissions of facts constitute
Federal Criminal Violations. See 18 U.S. C. 1001 and 15 U.S.C. 78ff(a)
/s/ Alison Taunton-Rigby 10/31/96
_________________________________________ ___________________
**Signature of Reporting Person Date
Note. File three copies of this form, one of which must be manually signed.
If space provided is insufficient, See Instruction 6 for procedure.
(Print or Type Responses)
|
|